Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma

Trial Profile

Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Salivary gland cancer
  • Focus Therapeutic Use
  • Acronyms PACSA
  • Most Recent Events

    • 23 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top